FOLFOX

In metastatic colorectal cancer, a combination of Leucovorin (LV) and fluorouraci (l FU) with oxaliplatin (FOLFOX) is a standard first-line regimen. The two limiting toxicities of FOLFOX are neutropenia and the specific reversible sensory neuropathy of oxaliplatin. The cumulative neurotoxicity often...

Full description

Saved in:

Bibliographic Details
Published in:	Gan to kagaku ryoho Vol. 33; no. 7; p. 911
Main Authors:	Mishima, Hideyuki, Ikenaga, Masakazu, Tsujinaka, Toshimasa, Yasui, Masayoshi, Kashiwazaki, Masaki, Miyazaki, Michihiko, Hirao, Motohiro, Fujitani, Kazumasa, Nakamori, Shouji
Format:	Journal Article
Language:	Japanese
Published:	Japan 01-07-2006
Subjects:	Anaphylaxis - chemically induced Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Drug Administration Schedule Fluorouracil - administration & dosage Fluorouracil - adverse effects Guideline Adherence Humans Leucovorin - administration & dosage Leucovorin - adverse effects Neoplasms - drug therapy Neutropenia - chemically induced Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Practice Guidelines as Topic
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In metastatic colorectal cancer, a combination of Leucovorin (LV) and fluorouraci (l FU) with oxaliplatin (FOLFOX) is a standard first-line regimen. The two limiting toxicities of FOLFOX are neutropenia and the specific reversible sensory neuropathy of oxaliplatin. The cumulative neurotoxicity often requires therapy to be stopped. Immediate hypersensitive reactions (anaphylaxis) have been noted as often as to 0.6 percent. We should pay sufficient attention to side effects of FOLFOX.
ISSN:	0385-0684